NCT05914753

Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

A Prospective Clinical Study Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Zhejiang Provincial People's Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the effectiveness of Xihuang Pill in improving the efficacy of neoadjuvant chemotherapy for breast cancer

Detailed description

1. To evaluate the safety and effectiveness of Xihuang Pill in improving the efficacy of neoadjuvant chemotherapy for breast cancer under the condition of widespread use. 2. To provide data support for improving the efficacy of neoadjuvant chemotherapy for clinical breast cancer patients.

Conditions

• Breast Cancer
• Chemotherapy Effect

Interventions

Type	Name	Description
DRUG	Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel	Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
DRUG	Epirubicin, Cyclophosphamide, Docetaxel	Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles

Timeline

• Start date: 2023-07-01
• Primary completion: 2024-06-01
• Completion: 2025-06-01
• First posted: 2023-06-22
• Last updated: 2023-06-22